中文摘要：

目的观察体外实验中乳源免疫调节肽（PGPIPN）与抗癌药物顺铂（DDP）联合用药对卵巢癌细胞增殖和迁移的影响。方法 MTS检测DDP联合PGPIPN对原代卵巢癌细胞增殖抑制情况,流式细胞术检测DDP联合PGPIPN对原代卵巢癌细胞凋亡率和周期的影响,细胞划痕实验检测细胞迁移能力。结果 MTS实验表明PGPIPN联合DDP处理组对卵巢癌细胞抑制率显著高于单独用DDP组,差异有统计学意义（P〈0.05）,且呈剂量和时间依赖性。流式细胞术显示PGPIPN可以协同DDP促进人原代卵巢癌细胞的凋亡,并使得肿瘤细胞停滞于G0/G1期。细胞划痕实验显示联合用药明显抑制细胞的运动能力,与单独用药差异有统计学意义（P〈0.05）。结论 PGPIPN可以提高DDP对原代卵巢癌细胞的作用。

英文摘要：

Objective To observe the concomitant therapy effect of immunomodulating peptide （PGPIPN） and anti- cancer drug cisplatin （DDP） on the proliferation and migration of ovarian cancer cells in vitro. Methods The inhib- itory action of DDP with PGPIPN on the proliferation of primary ovarian cancer cells were detected by MTS. Apop- totic ratios and cell cycle of primary ovarian cancer cells were measured by flow cytometry. Cell scratch assays were carried out to test cells＇migration. Results The result of MTS showed that the inhibition rate of the concomitant group against ovarian cancer cells was significantly higher than the group treated only with DDP. The difference was significant （P 〈 0. 05 ） and in a dose and time dependent manner. Flow cytometry results showed that PGPIPN could promote the apoptosis of human primary ovarian cancer cells by DDP, and the cycle of cells was arrested in GO/G1 phase. Cell scratch assays showed that concomitant therapy significantly inhibited cell movement, of which the difference from the group treated only with DDP of statistical significance （ P 〈 0. 05 ）. Conclusion PGPIPN can improve the effect of DDP on primary ovarian cancer cells.